|
Delayed
Canadian Securities Exchange
21:48:09 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.005000 CAD | -.--% |
|
-.--% | -66.67% |
| Market Cap | 671K 485K 417K 393K 359K 45.8M 673K 4.64M 1.8M 23.5M 1.82M 1.78M 75.69M | P/E 2024 |
-1.31x | P/E 2025 | -4.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.17M 1.57M 1.35M 1.27M 1.16M 148M 2.18M 15.02M 5.83M 76.05M 5.89M 5.77M 245M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
77.22% | Yield 2024 * |
-
| Yield 2025 | - |
Canadian Securities ExchangeCAD
| Markets | Quality | ||
|---|---|---|---|
Canadian Securities Exchange
| PHRX | Delayed | |
OTC Markets
| LMLLF | Delayed | |
|
Deutsche Boerse AG
| G11 | Delayed | |
|
Boerse Muenchen
| G11 | Real-time |
| 1 month | -50.00% | ||
| 6 months | -66.67% | ||
| Current year | -66.67% |
| 1 month | 0 |  | 0.01 |
| Current year | 0 | | 0.02 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.08 |
| 5 years | 0 | | 0.46 |
| 10 years | 0 | | 4.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Appleby
DFI | Director of Finance/CFO | 50 | 20/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 82 | 20/12/2016 |
David Kideckel
CHM | Chairman | - | 27/02/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/10/25 | Other | Chairman | 1,380,000 | 1.2929% | ||
| 03/05/24 | Other | Director | 0 | 0% | ||
| 03/05/24 | Option | Director | 500,000 | 0.5718% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | -50.00% | -85.71% | 487K | |
| -0.87% | +2.27% | +32.14% | +124.42% | 107B | |
| -0.61% | +5.24% | +65.29% | +184.02% | 57.82B | |
| +0.37% | +3.05% | -12.62% | +239.62% | 22.27B | |
| +1.09% | +2.15% | -10.06% | -6.84% | 8.16B | |
| -0.33% | -1.12% | -39.25% | -28.26% | 7.17B | |
| -0.59% | +6.52% | +4.95% | +25.41% | 6.83B | |
| +1.49% | -0.76% | -15.01% | -31.03% | 6.15B | |
| -0.24% | -1.72% | -6.17% | +19.88% | 5.13B | |
| +1.71% | +6.91% | +307.32% | +490.38% | 4.5B | |
| Average | +0.22% | +2.27% | +27.66% | +93.19% | 22.54B | |
| Weighted average by Cap. | -0.45% | +3.03% | +34.93% | +139.16% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -793K -573K -493K -464K -424K -54.13M -795K -5.49M -2.13M -27.77M -2.15M -2.11M -89.48M | -383K -277K -238K -224K -205K -26.16M -384K -2.65M -1.03M -13.42M -1.04M -1.02M -43.24M |
| Net Debt | 1.27M 921K 792K 745K 681K 86.94M 1.28M 8.81M 3.42M 44.6M 3.46M 3.38M 144M | 1.5M 1.08M 933K 878K 802K 102M 1.5M 10.38M 4.03M 52.55M 4.07M 3.98M 169M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/08/26 | CA$0.005000 | -.--% | 10,350 |
| 27/08/26 | CA$0.005000 | -50.00% | 37,000 |
| 26/08/26 | CA$0.0100 | +100.00% | 14,609 |
- Stock Market
- Stocks
- PHRX Stock
Select your edition
All financial news and data tailored to specific country editions
